Back to Search
Start Over
The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)-Data from POLISH MIS-C Registry.
- Source :
-
Children (Basel, Switzerland) [Children (Basel)] 2022 Feb 01; Vol. 9 (2). Date of Electronic Publication: 2022 Feb 01. - Publication Year :
- 2022
-
Abstract
- Background: Multisystem inflammatory syndrome (MIS-C) is a condition related to COVID-19. It's most significant feature is cardiac involvement.<br />Methods: We have analyzed data from 42 hospitals in the Polish MIS-C Registry. To compare the effect of GCS on fever, we formed two groups: the first treated with IVIG and the second treated with IVIG+GCS.<br />Results: There were 111 boys and 56 girls; the mean age was 8.57 years. All the patients were treated with IVIG: 76 patients with IVIG only, and 91 patients with IVIG+GCS. There were no statistically significant differences between the groups regarding age, gender, BMI, or inflammatory markers. Methylprednisolone was the most common drug (80%). Echocardiographic abnormalities on admission were more prevalent in the IVIG+GCS group. Mean time from IVIG infusion to subsidence of fever was 1.1 days, and 1.5 for those in the IVIG+GCS group.<br />Conclusions: GCS are commonly used in the treatment of MIS-C patients in Poland. Various GCS regimens are used, from a single dose to a month-long therapy. Children with lower lymphocyte levels and cardiac abnormalities on an echocardiographic examination performed on admission were more likely to receive GCS+IVIG. The effect of GCS is difficult to access as patients were not randomly assigned to receive the treatment.
Details
- Language :
- English
- ISSN :
- 2227-9067
- Volume :
- 9
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Children (Basel, Switzerland)
- Publication Type :
- Academic Journal
- Accession number :
- 35204900
- Full Text :
- https://doi.org/10.3390/children9020178